Third agent

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

HIV-1 Infection

Phase 3

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

CompletedNCT02616783

Gilead SciencesHIV-1 Infection

Start: 2015-12-22End: 2018-03-21Updated: 2020-03-04

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

CompletedNCT03631732

Gilead SciencesHIV-1 Infection

Start: 2018-08-28End: 2020-08-19Updated: 2021-09-05

Related Papers

High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence

Journal of Medical Virology2024-10-0110 citations

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with <scp>HIV</scp>: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

HIV Medicine2022-05-0838 citations

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

JAIDS Journal of Acquired Immune Deficiency Syndromes2021-05-2438 citations

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial.

2021-03-0939 citations

Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.

2019-10-0136 citations